No Data
No Data
A Struggling Pfizer Looks for Help From a Wall Streeter
Andrew Baum, a Citigroup drug-company analyst and its head of global healthcare, hasn't had a Buy rating on Pfizer shares for over a decade, and he has pulled his target price down as the stock has fallen. But on Monday, Pfizer said it was hiring him to be its chief strategy and innovation officer.
Express News | NYSE Order Imbalance 331307.0 Shares on Buy Side
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma. Extracellular vesicles contribute to
Merck's (NYSE:MRK) Investors Will Be Pleased With Their Notable 90% Return Over the Last Three Years
The MSD (MRK.US) KeyTruda combined chemotherapy-adjuvant treatment of high-risk endometrial cancer phase III study did not reach the main end
The Zhitong Finance App learned that on May 9, MSD (MRK.US) announced that the PD-1 inhibitor Keytruda (pabolizumab) combined chemotherapy (with or without radiotherapy) as adjuvant treatment for newly diagnosed and surgically treated high-risk endometrial cancer patients did not reach the main end point of disease-free survival (DFS). In the US, Keytruda has been approved for two indications for endometrial cancer treatment. Keytruda has a comprehensive clinical development plan for endometrial cancer treatment, including NRG-GY018
Drugmakers in Medicare Price Negotiations Spent Less on Research Than on Shareholder Payments, Marketing and Overhead: Report
No Data
Xiaobie : how do you read TRIPLE?